Literature DB >> 16960721

Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population.

GuoXiang Wang1, Hui Zhang, FeiFang He, XiangMing Fang.   

Abstract

OBJECTIVE: The CYP2D6*10 allele is the most common allele with a frequency ranging from 51.3 to 70% and correlated with a significantly reduced metabolic activity in a Chinese population. The aim of the present study was to investigate whether the CYP2D6*10 allele has an impact on the postoperative analgesia effect of tramadol in Chinese patients recovering from major abdominal surgery.
METHODS: A prospective study design was used and 70 gastric cancer patients recovering from gastrectomy were enrolled. After receiving a loading dose i.v., patients could self-administer doses of the drug combination (10 mg/ml tramadol plus 0.3 mg/ml metoclopramide) via patient-controlled analgesia (PCA). Blood samples were collected after induction of anesthesia. The CYP2D6*10 C188T polymorphism was analyzed by means of polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP). Demographic data among groups with different genotypes were analyzed using analysis of variance. The total consumption of tramadol between the three genotype groups for 48 h was compared.
RESULTS: The allele frequency of CYP2D6*10 is 52.4%; patients were categorized into three groups according to the CYP2D6 genotype: patients without CYP2D6*10 (group I, n=17), patients heterozygous for CYP2D6*10 (group II, n=26), and patients homozygous for CYP2D6*10 (group III, n=20). The demographic data among the three groups were comparable. The total consumption of tramadol for 48 h in group III was significantly higher than that in groups I and II, while it did not differ between groups I and II.
CONCLUSIONS: This study indicates that the CYP2D6*10 allele has significant impact on analgesia with tramadol in a Chinese population. Pharmacogenetics may explain some of the varying responses to pain medication in postoperative patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960721     DOI: 10.1007/s00228-006-0191-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

Review 1.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

Authors:  L DiAnne Bradford
Journal:  Pharmacogenomics       Date:  2002-03       Impact factor: 2.533

Review 2.  [Genetic polymorphism and drug interactions: their importance in the treatment of pain].

Authors:  Caroline F Samer; Valérie Piguet; Pierre Dayer; Jules A Desmeules
Journal:  Can J Anaesth       Date:  2005-10       Impact factor: 5.063

3.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

Authors:  C Sachse; J Brockmöller; S Bauer; I Roots
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

4.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

Authors:  I Johansson; M Oscarson; Q Y Yue; L Bertilsson; F Sjöqvist; M Ingelman-Sundberg
Journal:  Mol Pharmacol       Date:  1994-09       Impact factor: 4.436

5.  Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.

Authors:  Wei-Min Cai; Jun Xu; Bing Chen; Fu-Min Zhang; Yuan-Zhu Huang; Yin-Di Zhang
Journal:  Acta Pharmacol Sin       Date:  2002-11       Impact factor: 6.150

Review 6.  Clinical pharmacology of tramadol.

Authors:  Stefan Grond; Armin Sablotzki
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Visual analog scales for assessing surgical pain.

Authors:  Martin McCarthy; Chih-Hung Chang; A Simon Pickard; Anita Giobbie-Hurder; Donald D Price; Olga Jonasson; James Gibbs; Robert Fitzgibbons; Leigh Neumayer
Journal:  J Am Coll Surg       Date:  2005-08       Impact factor: 6.113

8.  Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.

Authors:  Kazushi Sawamura; Yutaro Suzuki; Toshiyuki Someya
Journal:  Eur J Clin Pharmacol       Date:  2004-09-03       Impact factor: 2.953

Review 9.  PM frequencies of major CYPs in Asians and Caucasians.

Authors:  Takaharu Mizutani
Journal:  Drug Metab Rev       Date:  2003 May-Aug       Impact factor: 4.518

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

View more
  19 in total

1.  Allelic and genotype frequencies of catechol-O-methyltransferase (Val158Met) and CYP2D6*10 (Pro34Ser) single nucleotide polymorphisms in the Philippines.

Authors:  Michael O Baclig; Rey Z Predicala; Cynthia A Mapua; Jingky P Lozano-Kühne; Maria Luisa G Daroy; Filipinas F Natividad; Francis O Javier
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

2.  Pharmacokinetics of tramadol is affected by MDR1 polymorphism C3435T.

Authors:  Ondrej Slanar; Milan Nobilis; Jaroslav Kvétina; Olga Matousková; Jeffrey R Idle; Frantisek Perlík
Journal:  Eur J Clin Pharmacol       Date:  2007-01-30       Impact factor: 2.953

Review 3.  Molecular epidemiology, cancer-related symptoms, and cytokines pathway.

Authors:  Cielito C Reyes-Gibby; Xifeng Wu; Margaret Spitz; Razelle Kurzrock; Michael Fisch; Eduardo Bruera; Sanjay Shete
Journal:  Lancet Oncol       Date:  2008-08       Impact factor: 41.316

4.  PharmGKB summary: tramadol pathway.

Authors:  Li Gong; Ulrike M Stamer; Mladen V Tzvetkov; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-07       Impact factor: 2.089

Review 5.  Precision medicine: does ethnicity information complement genotype-based prescribing decisions?

Authors:  Rashmi R Shah; Andrea Gaedigk
Journal:  Ther Adv Drug Saf       Date:  2017-12-01

6.  Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients.

Authors:  Hong Dong; Shu-Jun Lu; Rui Zhang; Dong-Dong Liu; Yan-Zhuo Zhang; Chun-Yu Song
Journal:  Eur J Clin Pharmacol       Date:  2015-05-08       Impact factor: 2.953

7.  Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.

Authors:  Hironari Tanaka; Takafumi Naito; Hikaru Sato; Takanori Hiraide; Yasuhide Yamada; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2018-07-26       Impact factor: 2.953

Review 8.  The Pharmacogenetics of Tramadol.

Authors:  Dorte Lassen; Per Damkier; Kim Brøsen
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein.

Authors:  Mouna Kanaan; Youssef Daali; Pierre Dayer; Jules Desmeules
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-05-26       Impact factor: 4.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.